spacer
home > ebr > spring 2019 >
PUBLICATIONS
European Biopharmaceutical Review


Rate this article You must be a member of the site to make a vote.  
Average rating:
1
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the bodys immune system
More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world in Europe and Asia in particular disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than todays differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. Its also important to choose a solution that enables multi-phase implementation
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIGs flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This years focus, A Look Back to the Future is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement